SLSanna Laurila

Sanna Laurila

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sanna Laurila has a total of 92 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Tissue‐specific insulin sensitivity in anorexia nervosa: A cross‐sectional positron emission tomography ( PET ) study in female adults

    by Aino Latva‐Rasku, Kyoungjune Pak, Eleni Rebelos, Miikka‐Juhani Honka, Prince Dadson, Jukka Koffert, Jouni Tuisku, Laura Pekkarinen, Sanna Laurila, Janina Hieta, et al.

    Anorexia nervosa (AN) has been linked to both impaired and improved whole‐body insulin sensitivity, but tissue‐specific metabolic alterations remain unexplored. To address this gap, we studied 12 female volunteers with recently diagnosed AN and 13 healthy, lean female controls in a cross‐sectional design using positron emission tomography (PET) imaging with the glucose analogue [ 18 F]FDG tracer under hyperinsulinemic conditions. We show that tissue‐specific glucose uptake during hyperinsulinemia was higher only in the duodenum of individuals with AN, but comparable in other tissues, possibly indicating altered intestinal glucose handling and nutrient sensing in reduced energy intake. In five participants with AN, glucose uptake was elevated despite reduced skeletal muscle glucose utilization. In controls, growth hormone (GH) levels correlated with skeletal muscle, liver, and brain insulin sensitivity, but these associations were absent in AN, suggesting disrupted endocrine regulation of glucose metabolism. Overall, whole‐body insulin sensitivity was not altered, yet tissue‐specific glucose metabolism exhibited greater variability in AN. These differences were not directly explained by disease duration or weight loss severity, suggesting contributions from individual genetic background and behavioral patterns.

  • Intranasal insulin affects brain, but not peripheral tissue, glucose uptake in lean, healthy men: a positron emission tomography study

    by Aino Latva-Rasku, Sanna Laurila, Tomi Karjalainen, Riku Klén, Eliisa Löyttyniemi, Olli Eskola, Lauri Nummenmaa, Martin Heni, Pirjo Nuutila

    In previous studies using functional magnetic resonance imaging, lean, healthy males have been shown to be most susceptible to the effects on intranasal insulin, with direct central insulin exposure also thought to enhance peripheral metabolism. However, in the current study, insulin nasal sprays failed to alter hepatic, skeletal muscle, or adipose tissue glucose metabolism but did induce a global decrease in brain glucose uptake.


  • SGLT2 Inhibitor Dapagliflozin Increases Skeletal Muscle and Brain Fatty Acid Uptake in Individuals With Type 2 Diabetes: A Randomized Double-Blind Placebo-Controlled Positron Emission Tomography Study

    by Aino Latva-Rasku, Eleni Rebelos, Jouni Tuisku, Richard Aarnio, Achol Bhowmik, Helmi Keskinen, Sanna Laurila, Minna Lahesmaa-Hatting, Laura Pekkarinen, Henrik Isackson, et al.

    OBJECTIVE: The aim of this study was to investigate the impact of the sodium–glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin on tissue fatty acid (FA) uptake in the skeletal muscle, brain, small intestine, and subcutaneous and visceral adipose tissue of individuals with type 2 diabetes by using positron emission tomography (PET). RESEARCH DESIGN AND METHODS: In a 6-week randomized double-blind placebo-controlled trial, 53 patients with type 2 diabetes treated with metformin received either 10 mg dapagliflozin or placebo daily. Tissue FA uptake was quantified at baseline and end of treatment with PET and the long-chain FA analog radiotracer 14(R,S)-[18F]fluoro-6-thia-heptadecanoic acid. Treatment effects were assessed using ANCOVA, and the results are reported as least square means and 95% CIs for the difference between groups. RESULTS: A total of 38 patients (dapagliflozin n = 21; placebo n = 17) completed the study. After 6 weeks, skeletal muscle FA uptake was increased by dapagliflozin compared with placebo (1.0 [0.07, 2.0] μmol ⋅ 100 g−1 ⋅ min−1; P = 0.032), whereas uptake was not significantly changed in the small intestine or visceral or subcutaneous adipose tissue. Dapagliflozin treatment significantly increased whole-brain FA uptake (0.10 [0.02, 0.17] μmol ⋅ 100 g−1 ⋅ min−1; P = 0.01), an effect observed in both gray and white matter regions. CONCLUSIONS: Six weeks of treatment with dapagliflozin increases skeletal muscle and brain FA uptake, partly driven by a rise in free FA availability. This finding is in accordance with previous indirect measurements showing enhanced FA metabolism in response to SGLT2 inhibition and extends the notion of a shift toward increased FA use to muscle and brain.


  • Open Access

    Insulin-stimulated brain glucose uptake correlates with brain metabolites in severe obesity: A combined neuroimaging study

    by Eleni Rebelos, Aino Latva-Rasku, Kalle Koskensalo, Laura Pekkarinen, Ekaterina Saukko, Jukka Ihalainen, Miikka-Juhani Honka, Jouni Tuisku, Marco Bucci, Sanna Laurila, et al.

    The human brain undergoes metabolic adaptations in obesity, but the underlying mechanisms have remained largely unknown. We compared concentrations of often reported brain metabolites measured with magnetic resonance spectroscopy (1H-MRS, 3 T MRI) in the occipital lobe in subjects with obesity and lean controls under different metabolic conditions (fasting, insulin clamp, following weight loss). Brain glucose uptake (BGU) quantified with 18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET)) was also performed in a subset of subjects during clamp. In dataset A, 48 participants were studied during fasting with brain 1H-MRS, while in dataset B 21 participants underwent paired brain 1H-MRS acquisitions under fasting and clamp conditions. In dataset C 16 subjects underwent brain 18F-FDG-PET and 1H-MRS during clamp. In the fasting state, total N-acetylaspartate was lower in subjects with obesity, while brain myo-inositol increased in response to hyperinsulinemia similarly in both lean participants and subjects with obesity. During clamp, BGU correlated positively with brain glutamine/glutamate, total choline, and total creatine levels. Following weight loss, brain creatine levels were increased, whereas increases in other metabolites remained not significant. To conclude, insulin signaling and glucose metabolism are significantly coupled with several of the changes in brain metabolites that occur in obesity.


  • Open Access

    Secretin modulates appetite via brown adipose tissue-brain axis

    by Lihua Sun, Sanna Laurila, Minna Lahesmaa, Eleni Rebelos, Kirsi A. Virtanen, Katharina Schnabl, Martin Klingenspor, Lauri Nummenmaa, Pirjo Nuutila

    Purpose: Secretin activates brown adipose tissue (BAT) and induces satiation in both mice and humans. However, the exact brain mechanism of this satiety inducing, secretin-mediated gut-BAT-brain axis is largely unknown. Methods and results: In this placebo-controlled, single-blinded neuroimaging study, firstly using [18F]-fluorodeoxyglucose (FDG) PET measures (n = 15), we established that secretin modulated brain glucose consumption through the BAT-brain axis. Predominantly, we found that BAT and caudate glucose uptake levels were negatively correlated (r = -0.54, p = 0.037) during secretin but not placebo condition. Then, using functional magnetic resonance imaging (fMRI; n = 14), we found that secretin improved inhibitory control and downregulated the brain response to appetizing food images. Finally, in a PET-fMRI fusion analysis (n = 10), we disclosed the patterned correspondence between caudate glucose uptake and neuroactivity to reward and inhibition, showing that the secretin-induced neurometabolic coupling patterns promoted satiation. Conclusion: These findings suggest that secretin may modulate the BAT-brain metabolic crosstalk and subsequently the neurometabolic coupling to induce satiation. The study advances our understanding of the secretin signaling in motivated eating behavior and highlights the potential role of secretin in treating eating disorders and obesity. Trial registration: EudraCT no. 2016-002373-35, registered 2 June 2016; Clinical Trials no. NCT03290846, registered 25 September 2017.


  • Open Access

    Secretin modulates appetite via brown adipose tissue - brain axis

    by Lihua Sun, Sanna Laurila, Minna Lahesmaa, Eleni Rebelos, Kirsi A. Virtanen, Katharina Schnabl, Martin Klingenspor, Lauri Nummenmaa, Pirjo Nuutila

    Secretin activates brown adipose tissue (BAT) and induces satiation in both mice and humans. However, the exact brain mechanism of this satiety inducing, secretin-mediated gut-BAT-brain axis is unknown. In this placebo-controlled, single-blinded neuroimaging study, firstly using [ 18 F]FDG-PET measures (n = 15), we established that secretin modulated brain glucose consumption through the BAT-brain axis. Predominantly, we found that BAT and caudate glucose uptake levels were negatively correlated (r = −0.54, p = 0.037) during secretin but not placebo condition. Then, using functional magnetic resonance imaging (fMRI; n = 14), we found that secretin down-regulated the brain response to appetizing food images and improved inhibitory control. Finally, in a PET-fMRI fusion analysis (n = 10), we disclosed the patterned correspondence between caudate glucose uptake and neuroactivity to reward and inhibition, showing that the secretin-induced neurometabolic coupling pattern promoted satiation. These findings suggest that secretin modulates the BAT-brain metabolic crosstalk and subsequent neurometabolic coupling to induce satiation, bearing potential clinical benefits for treating eating disorders. Significance of the study: Secretin activates brown adipose tissue and induces satiation, but the underlying brain mechanisms are still unclear. This placebo-controlled PET-fMRI study uses brain metabolic and BOLD measures to dissect the modulatory effects of secretin on brain functions associative to satiation. Findings show that secretin i) modulates caudate glucose metabolism via the BAT-brain axis, ii) enhances BOLD response in inhibitory control, and iii) reduces reward-related BOLD response. Further evidence shows that these measured effects are tightly linked via the secretin-mediated brain neurometabolic coupling. This study significantly advances our knowledge on how secretin leads to satiation and highlights the potential role of secretin in treating eating disorders and obesity.


  • Open Access

    Photoperiod modulates mu-opioid receptor availability in brown adipose tissue

    by Lihua Sun, Richard Aarnio, Erika Atencio Herre, Salli Kärnä, Senthil Palani, Helena Virtanen, Heidi Liljenbäck, Jenni Virta, Aake Honkaniemi, Vesa Oikonen, et al.

    Photoperiod drives metabolic activity of brown adipose tissue (BAT), and affects food intake and weight gain in mammals. Sympathetic innervation in BAT controls thermogenesis and facilitates physiological adaption to seasons, but the exact mechanism remains elusive. Previous studies show that the central opioid signaling tunes BAT heating and the brain muopioid receptor (MOR) levels have seasonal patterns. It is hence intriguing to know whether the peripheral MOR signaling shows seasonal variation. Here, we examined the effect of photoperiod on BAT MOR availability using [ 11 C]carfentanil positron emission topography (PET). Adult rats (n = 9) were repeatedly imaged under changing photoperiods which simulates the local seasons. Long photoperiod downregulated MOR availability in BAT, while MOR availability in the muscles was unaffected. We confirmed the expression of MOR in BAT and muscle using immunofluorescence imaging. We conclude that photoperiod causally affects MOR availability in BAT, and sympathetic innervation of BAT may influence thermogenesis via the peripheral MOR system. Significance of the study: Photoperiod impacts the metabolic activity of brown adipose tissue (BAT) with the exact mechanism still unclear. The current study shows that photoperiod causally affects the mu-opioid receptor (MOR) levels in BAT, with longer photoperiod leading to lower MOR availability. This possibly indicates down-regulated innervation during bright seasons. Immunofluorescence staining data reveal expression of MOR in both brain and peripheral tissues, drawing attention to the under-investigated peripheral MOR system. Also, the study highlights the feasibility of [ 11 C]carfentanil PET in studying the peripheral MOR signaling.


  • Open Access

    Novel effects of the gastrointestinal hormone secretin on cardiac metabolism and renal function

    by Sanna Laurila, Eleni Rebelos, Minna Lahesmaa, Lihua Sun, Katharina Schnabl, Tia-Mari Peltomaa, Riku Klén, Mueez U-Din, Miikka-Juhani Honka, Olli Eskola, et al.

    The cardiac benefits of gastrointestinal hormones have been of interest in recent years. The aim of this study was to explore the myocardial and renal effects of the gastrointestinal hormone secretin in the GUTBAT trial (NCT03290846). A placebo-controlled crossover study was conducted on 15 healthy males in fasting conditions, where subjects were blinded to the intervention. Myocardial glucose uptake was measured with [18F]2-fluoro-2-deoxy-d-glucose ([18F]FDG) positron emission tomography. Kidney function was measured with [18F]FDG renal clearance and estimated glomerular filtration rate (eGFR). Secretin increased myocardial glucose uptake compared with placebo (secretin vs. placebo, means ± SD, 15.5 ± 7.4 vs. 9.7 ± 4.9 μmol/100 g/min, 95% confidence interval (CI) [2.2, 9.4], P = 0.004). Secretin also increased [18F]FDG renal clearance (44.5 ± 5.4 vs. 39.5 ± 8.5 mL/min, 95%CI [1.9, 8.1], P = 0.004), and eGFR was significantly increased from baseline after secretin, compared with placebo (17.8 ± 9.8 vs. 6.0 ± 5.2 ΔmL/min/1.73 m2, 95%CI [6.0, 17.6], P = 0.001). Our results implicate that secretin increases heart work and renal filtration, making it an interesting drug candidate for future studies in heart and kidney failure. NEW & NOTEWORTHY Secretin increases myocardial glucose uptake compared with placebo, supporting a previously proposed inotropic effect. Secretin also increased renal filtration rate.


  • Brown adipose tissue fat-fraction is associated with skeletal muscle adiposity

    by Madoka Ogawa, Kalle Koskensalo, Sanna Laurila, Milja Holstila, Minna Lahesmaa, Kirsi A. Virtanen, Hidehiro Iida, Hiroshi Akima, Pirjo Nuutila

    Purpose While brown adipose tissue (BAT) activity is known to be associated with both muscle and adipose tissue volumes, the association between BAT and muscle composition remains unclear, especially in adults. Therefore, the present study aimed to examine the association between BAT parameters (glucose uptake and fat-fraction) and muscle volumes and intramuscular adipose tissue contents among healthy young and middle-aged men. Methods BAT glucose uptake was determined using positron emission tomography with [18F]-2-deoxy-2-fluoro-D-glucose (18F-FDG) during cold exposure in 19 young and middle-aged men (36.3 ± 10.7 years). The fat-fraction of BAT was determined from volumes of interest set in cervical and supraclavicular adipose tissue depots using signal fat-fraction maps via magnetic resonance imaging (MRI). Muscle volumes and intramuscular adipose tissue contents of m. tibialis anterior and m. multifidus lumborum were measured using MRI. Results The fat-fraction of BAT was significantly associated with intramuscular adipose tissue content in m. tibialis anterior (n = 13, rs = 0.691, P = 0.009). A similar trend was also observed in m. multifidus lumborum (n = 19, rs = 0.454, P = 0.051). However, BAT glucose uptake was not associated with intramuscular adipose tissue contents in both muscles, nor were muscle volumes associated with the BAT glucose uptake and fat-fraction. Conclusion The fat-fraction of BAT increases with skeletal muscle adiposity, especially in the lower leg, among healthy young and middle-aged men.


  • Secretin-Activated Brown Fat Mediates Prandial Thermogenesis to Induce Satiation

    by Yongguo Li, Katharina Schnabl, Sarah-Madeleine Gabler, Monja Willershäuser, Josefine Reber, Angelos Karlas, Sanna Laurila, Minna Lahesmaa, Mueez U Din, Andrea Bast-Habersbrunner, et al.